Research background · Updated November 1, 2026
Tirzepatide Research: Publications, Study Types and Background
Short answer
Tirzepatide is listed as dual GIP and GLP-1 receptor agonist peptide. As of November 1, 2026, PubMed indexes 2,710 records matching Tirzepatide, the earliest from 1994; 1,553 were published in 2021–2025 and 988 are reviews. ClinicalTrials.gov lists 328 registered studies matching the compound.
- PubMed records
- 2,710
- Earliest record
- 1994
- Published 2021–2025
- 1,553
- Reviews
- 988
- Animal-only studies
- 78
- Registered studies
- 328
Publications per year, 2006–2025
1,675 records in 2016–2025 against 3 in 2006–2015; the busiest year was 2025, with 902.
See the numbers
| Year | PubMed records |
|---|---|
| 2006 | 1 |
| 2007 | 0 |
| 2008 | 0 |
| 2009 | 0 |
| 2010 | 0 |
| 2011 | 0 |
| 2012 | 2 |
| 2013 | 0 |
| 2014 | 0 |
| 2015 | 0 |
| 2016 | 0 |
| 2017 | 0 |
| 2018 | 0 |
| 2019 | 0 |
| 2020 | 10 |
| 2021 | 36 |
| 2022 | 112 |
| 2023 | 221 |
| 2024 | 394 |
| 2025 | 902 |
Study types
| All PubMed records | 2,710 |
|---|---|
| Reviews | 98836% |
| Animal studies (no human subjects indexed) | 783% |
| Indexed as clinical trials | 1465% |
| Registered on ClinicalTrials.gov | 328 |
Categories overlap and follow PubMed’s own indexing; recent records may not be indexed yet.
Primary research directions
What 3 of the most-cited and most recent Tirzepatide papers report, in their own authors’ terms. Each line links the paper it came from.
Dual GIP and GLP-1 receptor signaling
This pharmacology study reports that tirzepatide mimics native GIP at the GIP receptor but is biased at the GLP-1 receptor toward cAMP generation over beta-arrestin recruitment, and calculates greater engagement of the GIP receptor than the GLP-1 receptor.
CellsWillard FS 2020JCI insightPMID 32730231
Pancreatic islet function and insulin sensitivity
In a post hoc analysis of a trial in 316 people with type 2 diabetes, a marker of beta-cell function rose and proinsulin ratios fell with tirzepatide against placebo, and insulin sensitivity markers improved by more than weight loss alone explained.
HumansThomas MK 2021The Journal of clinical endocrinology and metabolismPMID 33236115
Appetite and satiety signaling
This review of the two incretins tirzepatide targets states that GIP and GLP-1 each help regulate food intake by acting on neurons in the brain's satiety center and each stimulate insulin secretion from pancreatic beta cells, while differing in their effects on glucagon.
ReviewLiu QK 2024Frontiers in endocrinologyPMID 39114288
Most-studied topics
The Medical Subject Headings (MeSH) PubMed indexers most often marked as a main topic, across 400 of the 2,710 records. They describe what the literature is about, not what Tirzepatide does.
- Diabetes Mellitus, Type 2136 papers
- Tirzepatide90 papers
- Obesity87 papers
- Hypoglycemic Agents87 papers
- Glucagon-Like Peptide-1 Receptor Agonists41 papers
- Anti-Obesity Agents40 papers
- Glucagon-Like Peptides35 papers
- Gastric Inhibitory Polypeptide33 papers
Key papers
Earliest indexed record
Author not listed (1994). .
PMID 39038307Most-cited paper · 1,646 citations
Frías JP (2021). The New England journal of medicine.
PMID 34170647Most-cited #2 · 856 citations
Rosenstock J (2021). Lancet (London, England).
PMID 34186022Most-cited #3 · 851 citations
Loomba R (2024). The New England journal of medicine.
PMID 38856224
Citation counts from NIH iCite, among the 400 records sampled. Titles are left out; open each record on PubMed to read it.
Identity
| Synonyms and codes | VLP-2 (TR) |
|---|---|
| Description | Dual GIP and GLP-1 receptor agonist peptide |
| Supplied form | Lyophilized powder |
As published by Vanta Labs, with its sources, on the Tirzepatide page.
How these numbers were counted
- PubMed search, run November 1, 2026:
tirzepatide[tiab]re-run it. Study types add PubMed’s own filters (review, clinical trial, animals not humans). - Topics: MeSH major-topic headings counted across up to 400 of the matching records; headings for study set-up (species, sex, age) are left out.
- Citations: NIH iCite citation counts for the same records.
- ClinicalTrials.gov search:
tirzepatidere-run it. Any phase, any status.
This page reports what has been published and what papers say they found, with each source linked. It gives no dosing or usage information, and nothing here is a reason to use Tirzepatide outside a laboratory.
Wholesale supply
Tirzepatide for research, documented lot by lot.
5mg, 10mg, 20mg, 30mg vials, with a published report printing 99.581% HPLC purity. Every wholesale lot comes with its certificate of analysis, and your quote names the lot. Pricing on inquiry.
Tirzepatide research questions
How much research has been published on Tirzepatide?
PubMed indexes 2,710 records matching Tirzepatide (searched November 1, 2026), including 988 reviews and 146 records indexed as clinical trials. 1,553 were published in the five years 2021–2025.
When was Tirzepatide first described in the literature?
The earliest PubMed record matching Tirzepatide is from 1994 (first author not listed, , PMID 39038307).
What topics does the Tirzepatide literature cover?
The subject headings PubMed indexers most often marked as a main topic of Tirzepatide papers are Diabetes Mellitus, Type 2, Tirzepatide, Obesity, Hypoglycemic Agents. These describe what the literature is about. Findings from individual papers, with their sources, are summarized on this page.
Is Tirzepatide sold for human use?
No. Vanta Foundry supplies it for laboratory research use only. Not for human or veterinary use, and not a drug, food, cosmetic or dietary supplement.
Where can I buy Tirzepatide wholesale for research?
From the Vanta Foundry wholesale catalog: add it to your list, choose sizes and the number of vials, and send it on WhatsApp or by email. Every wholesale lot comes with a certificate of analysis.
Research materials supplied by Vanta Foundry are for laboratory research use only. They are not for human or veterinary use and are not drugs, foods, cosmetics or dietary supplements. Websites and payment processing are business services for research-supply brands.
All compounds: research peptide publication statistics.